BACKGROUND: Scavenger Receptor Class B Type I (SR-BI) facilitates influx of cholesterol to the cell from lipoproteins in the circulation. This influx of cholesterol may be important for many cellular functions, including synthesis of androgens. Castration-resistant prostate cancer tumors are able to synthesize androgens de novo in order to supplement the loss of exogenous sources often induced by androgen deprivation therapy. Silencing of SR-BI may impact the ability of prostate cancer cells, particularly those of castration-resistant state, to maintain the intracellular supply of androgens by removing a supply of cholesterol. METHODS: SR-BI expression was knocked down using small interfering RNA in LNCaP and C4-2 cells. The effect of down-regulation of SR-BI on PSA production, cell toxicity, and cell viability was measured in both cell types. In addition, compensatory cholesterol synthesis activity was measured using the radiolabeled precursor, (14) C-acetate. RESULTS: SR-BI protein expression is higher basally in C4-2 cells than LNCaP cells. Silencing of SR-BI expression to greater than 85% reduced PSA production in LNCaP and C4-2 SRBI-KD cells by 55% and 58% compared to negative control cells, respectively. SR-BI-KD C4-2 cells demonstrated significantly reduced cell viability (>25%) compared the NC cells. CONCLUSIONS: The down-regulation of SR-BI significantly impacts PSA production of prostate cancer cells, as well as the viability of C4-2 cells in the presence and absence of HDL. This may indicate a deficiency in cholesterol availability to the androgen synthesis pathway or may implicate a role for SR-BI in prostate cancer signal transduction pathways.
BACKGROUND:Scavenger Receptor Class B Type I (SR-BI) facilitates influx of cholesterol to the cell from lipoproteins in the circulation. This influx of cholesterol may be important for many cellular functions, including synthesis of androgens. Castration-resistant prostate cancer tumors are able to synthesize androgens de novo in order to supplement the loss of exogenous sources often induced by androgen deprivation therapy. Silencing of SR-BI may impact the ability of prostate cancer cells, particularly those of castration-resistant state, to maintain the intracellular supply of androgens by removing a supply of cholesterol. METHODS:SR-BI expression was knocked down using small interfering RNA in LNCaP and C4-2 cells. The effect of down-regulation of SR-BI on PSA production, cell toxicity, and cell viability was measured in both cell types. In addition, compensatory cholesterol synthesis activity was measured using the radiolabeled precursor, (14) C-acetate. RESULTS:SR-BI protein expression is higher basally in C4-2 cells than LNCaP cells. Silencing of SR-BI expression to greater than 85% reduced PSA production in LNCaP and C4-2 SRBI-KD cells by 55% and 58% compared to negative control cells, respectively. SR-BI-KD C4-2 cells demonstrated significantly reduced cell viability (>25%) compared the NC cells. CONCLUSIONS: The down-regulation of SR-BI significantly impacts PSA production of prostate cancer cells, as well as the viability of C4-2 cells in the presence and absence of HDL. This may indicate a deficiency in cholesterol availability to the androgen synthesis pathway or may implicate a role for SR-BI in prostate cancer signal transduction pathways.
Authors: Konrad H Stopsack; Travis A Gerke; Jennifer A Sinnott; Kathryn L Penney; Svitlana Tyekucheva; Howard D Sesso; Swen-Olof Andersson; Ove Andrén; James R Cerhan; Edward L Giovannucci; Lorelei A Mucci; Jennifer R Rider Journal: Cancer Res Date: 2016-06-20 Impact factor: 12.701
Authors: Konrad H Stopsack; Travis A Gerke; Ove Andrén; Swen-Olof Andersson; Edward L Giovannucci; Lorelei A Mucci; Jennifer R Rider Journal: Carcinogenesis Date: 2017-08-01 Impact factor: 4.944
Authors: Jacob A Gordon; Jake W Noble; Ankur Midha; Fatemeh Derakhshan; Gang Wang; Hans H Adomat; Emma S Tomlinson Guns; Yen-Yi Lin; Shancheng Ren; Collin C Collins; Peter S Nelson; Colm Morrissey; Kishor M Wasan; Michael E Cox Journal: Cancer Res Date: 2019-05-07 Impact factor: 12.701
Authors: Teemu J Murtola; Heimo Syvälä; Pasi Pennanen; Merja Bläuer; Tiina Solakivi; Timo Ylikomi; Teuvo L J Tammela Journal: PLoS One Date: 2012-06-27 Impact factor: 3.240